Seaport Therapeutics, Inc. SPTX
21.97 USD +0.04 (+0.21%)
At closeNov 10, 2026, 4:00 PM EST
21.97 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
21.05 Day range 22.23
14.85 52-week range 28.38
- YTD
- +10.74%
- 1 year
- +10.74%
News
benzinga.com JP Morgan Maintains Overweight on Seaport Therapeutics, Raises Price Target to $41 JP Morgan analyst Tessa Romero maintains Seaport Therapeutics (NASDAQ:SPTX) with a Overweight and raises the price target from $40 to $41.
zacks.com How Much Upside is Left in Seaport Therapeutics, Inc (SPTX)? Wall Street Analysts Think 77.91% The mean of analysts' price targets for Seaport Therapeutics, Inc (SPTX) points to a 77.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong…
benzinga.com Seaport Therapeutics Q3 EPS $(0.49) Beats $(0.58) Estimate Seaport Therapeutics (NASDAQ:SPTX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.58) by 15.52 percent. This is a 94.8 percent increase over losses of…
benzinga.com This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.
benzinga.com Canaccord Genuity Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $28 Canaccord Genuity analyst Sumant Kulkarni initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $28.
benzinga.com Seaport Therapeutics To Present Phase 1 Clinical Data For GlyphAgo At The European College Of Neuropsychopharmacology Congress, October 10-13 Congress is taking place October 10-13, 2026, in Munich, Germany. The poster represents the first scientific presentation of data from the GlyphAgo Phase 1 program and provides detailed…
benzinga.com HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
benzinga.com This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Analysts initiated bullish coverage on TSEM, PGEN, SPTX, PDFS and CF, setting targets of $300, $12, $46, $60 and $162.- benzinga.com Raymond James Initiates Coverage On Seaport Therapeutics with Strong Buy Rating, Announces Price Target of $46 Raymond James analyst Tiago Fauth initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Strong Buy rating and announces Price Target of $46.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
- benzinga.com Seaport Therapeutics Reports Phase 1 Results; GlyphAllo At 375 mg Meets Primary Endpoint With No Driving Impairment; 250 mg Dose Also Achieves Key Secondary Endpoint Trial met its primary endpoint, showing that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5, following multiple-day dosingKey…
- benzinga.com Jones Trading Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $32 Jones Trading analyst Justin Walsh initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $32.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.- benzinga.com Seaport Therapeutics Q2 EPS $(1.78) Misses $(0.65) Estimate Seaport Therapeutics (NASDAQ:SPTX) reported quarterly losses of $(1.78) per share which missed the analyst consensus estimate of $(0.65) by 173.85 percent. This is a 72.19 percent increase over…
- benzinga.com HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50 HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $50.
benzinga.com Seaport Therapeutics Q1 EPS $(10.34) Misses $(9.48) Estimate Seaport Therapeutics (NASDAQ:SPTX) reported quarterly losses of $(10.34) per share which missed the analyst consensus estimate of $(9.48) by 9.07 percent.- benzinga.com Citigroup Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $35 Citigroup analyst Yigal Nochomovitz initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $35.
- benzinga.com Leerink Partners Initiates Coverage On Seaport Therapeutics with Outperform Rating, Announces Price Target of $35 Leerink Partners analyst Marc Goodman initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Outperform rating and announces Price Target of $35.
- benzinga.com JP Morgan Initiates Coverage On Seaport Therapeutics with Overweight Rating, Announces Price Target of $42 JP Morgan analyst Tessa Romero initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Overweight rating and announces Price Target of $42.
benzinga.com Stifel Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $30 Stifel analyst Paul Matteis initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $30.